IC
CMPX icon

Ikarian Capital’s Compass Therapeutics CMPX Stock Holding History

Ikarian Capital’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-662,200
Closed -$1.26M – 148
2025
Q1 		$1.26M Buy
+662,200
New +$1.76M 0.16% 87

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital's CMPX Position: Q1 2026 in Review

Ikarian Capital reduced its Compass Therapeutics (CMPX) stake by 98% in Q1 2026, selling an estimated $4.51M and leaving 18,000 shares worth $95.2K. The position accounts for 0.01% of the portfolio, ranked #149.

Ikarian Capital first reported a position in CMPX in Q4 2021 and has held it in 4 quarters since. The position peaked at $4.3M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • Ikarian Capital held 18,000 shares of Compass Therapeutics worth $95.2K as of Q1 2026.
  • Ikarian Capital sold 782,000 Compass Therapeutics shares in Q1 2026, an estimated $4.51M.
  • Compass Therapeutics made up 0.01% of Ikarian Capital's portfolio in Q1 2026, its #149 holding.
  • Ikarian Capital first reported a position in Compass Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • Ikarian Capital's Compass Therapeutics position peaked at $4.3M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.